Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 836 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 836 shares of the company’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $50.00, for a total transaction of $41,800.00. Following the transaction, the director now owns 278,109 shares of the company’s stock, valued at approximately $13,905,450. This represents a 0.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Pro-Dex Price Performance

Pro-Dex stock traded up $1.35 during midday trading on Monday, reaching $49.58. 28,636 shares of the stock traded hands, compared to its average volume of 22,246. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33. Pro-Dex, Inc. has a 12 month low of $16.84 and a 12 month high of $59.60. The stock’s fifty day moving average is $40.31 and its 200-day moving average is $40.26. The stock has a market cap of $161.68 million, a P/E ratio of 24.67 and a beta of 0.68.

Pro-Dex (NASDAQ:PDEX) last posted its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, equities research analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Hedge Funds Weigh In On Pro-Dex

A number of institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after acquiring an additional 529 shares in the last quarter. FMR LLC lifted its stake in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Pro-Dex by 8.1% during the fourth quarter. Renaissance Technologies LLC now owns 14,740 shares of the medical instruments supplier’s stock valued at $689,000 after buying an additional 1,100 shares during the period. Geode Capital Management LLC grew its stake in shares of Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Pro-Dex during the fourth quarter valued at approximately $202,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.